Arzeda
PrivateLast Round
Grant
Sep 8, 2025
Total Funding Raised
$62.55M
Momentum Score
25 /100
Company Overview
Arzeda is a synthetic biology company that creates and manufactures innovative designer proteins and enzymes, offering a diverse range of enzymes and specialty chemicals for various advanced applications, including polymers and pharmaceuticals, to help clients achieve superior performance, cost-effectiveness, and sustainability.
Sector
Frontier & Industrial Tech
Verticals
Biotechnology, Advanced Materials, Drug Discovery, ML Platforms, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arzeda Comps
Public and private peers based on sector, stage, and business model.
Arzeda Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 8, 2025 | ||||
| Grant | Sep 8, 2025 | ||||
| VC Round | Sep 17, 2024 | ||||
| Series B | Mar 30, 2022 | ||||
| Corporate Funding | Nov 24, 2020 | ||||
Series A | Nov 28, 2017 |
Key People
Founding team and executive leadership
Arzeda Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bunge Ventures | Series B, VC Round |
| Fall Line Capital | VC Round |
| Sucden Ventures | VC Round |
| WRF Capital | Series A |
| Conti Ventures | Series B |
| Universal Materials Incubator | Series B, Series A |
| Lewis & Clark Partners | Series B, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
Launched ViaLeaf Reb M, a revolutionary process using Nobel Prize-winning technology.
- Mar 5, 2026
Partnering on the new ViaLeaf Reb M process.
Arzeda Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Arzeda's valuation, stock price, and market status.
